Admescope launches new services to study drug transporters
Regulatory compliant package to investigate transporter-mediated drug-drug interactions
Uptakesubst evaluates if the cellular uptake of the test compound is facilitated by solute carrier (SLC) transporters OATP1B1, OATP1B3, OAT1, OAT3 and OCT2, OCT1, MATE1 and MATE2, while Uptakeinhib reveals if the test compound possesses inhibitory potential towards them. The assays are conducted with human embryonic kidney (HEK293) cells, which are transfected with a single human transporter gene. The optimised and validated assays are utilising LC/MS/MS as an analytical tool.
“Drug transporters can have a major role in pharmacokinetic, safety and efficacy profiles of drugs, emphasising the importance to study the potential transporter-
Dr Ari Tolonen, CEO at Admescope, continues; “We are truly committed to building a strong ADME-Tox service portfolio. The new services enable us to serve our customers even more effectively, as they complement our already well established drug interaction assays.”
Marketing Director, Admescope
+358 45 8799 032